Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
In blow to compounders, FDA reaffirms tirzepatide shortage is over The FDA has reaffirmed that the shortage of Eli Lillys blockbuster obesity and diabetes medications is resolved, dealing a blow to pharmacies and telehealth services Sign up to read this article for free
A physician-supervised plan can help answer whether the medication is appropriate, which option fits the patients risk profile, what dose should be used, how quickly the dose should increase, what side effects should be expected, when the dose should be held or adjusted, how much protein the patient should eat, how muscle can be preserved, what labs should be tracked, and what long-term maintenance should look like
Originally intended for the treatment of type 2 diabetes, clinical trials found that they are also able to treat obesity by significantly decreasing a patients appetite
It has been a very effective medication for lowering blood sugar for many years, with the added benefit of weight loss .[1] In response to the weight loss seen in patients with type II diabetes, Novo Nordisk sent semaglutide into FDA trials for approval as a weight loss medication
